Baidu
map

Lasers Med Sci:非热氮等离子体与长脉冲Nd:YAG激光在手部嫩肤中的疗效和安全性

2022-04-09 MedSci原创 MedSci原创

随着新的非侵入性方式的出现,越来越多的人考虑采用整体的身体年轻化方法,来尽量减少面部年轻化与包括手在内的身体其他部位之间的美容差异。

随着新的非侵入性方式的出现,越来越多的人考虑采用整体的身体年轻化方法,来尽量减少面部年轻化与包括手在内的身体其他部位之间的美容差异。近日,发表于Lasers Med Sci的一项随机对照研究探究了脉冲式非热大气压氮气等离子体与长脉冲Nd:YAG激光相比,在手部年轻化方面的多个治疗疗程的有效性和安全性。

为了优化氮气等离子体的嫩肤模式,在不同的输入功率和时间段,比较了反应性种类的相对强度和皮肤温度。研究共招募了25名轻度-中度光损伤皮肤的患者:随机选择一只手进行每周八次的等离子体治疗(两次),而另一只手则每月接受三次激光治疗(直到红斑变得明显)。

 

盲法皮肤科医生在第一次治疗后的1个月和2个月以及最后一次治疗后的1个月和3个月对受试者的手部皱纹和色斑的平均改善情况进行评分。评估了患者的满意度和皮肤的生物力学特征,包括皮肤共振运行时间(CRRT)、黑色素、经表皮失水(TEWL)和水合作用。

 

结果显示,临床上,两种方法都可以显著手部皱纹(等离子体和激光后分别为49.09±19.18%和39.32±18.21%)和色斑(等离子体和激光后分别为45.00±26.32%和30.62%±24.99%),且效果相似(P<0.05)。两种方法治疗后,CRRT和黑色素都有明显下降(P < 0.05)。值得注意的是,血浆疗法导致TEWL显著下降,并提高了皮肤的水合作用。而激光治疗则增强了TEWL,减少了皮肤的水合作用。

综上所述,该研究结果证实,冷等离子体与长脉冲Nd:YAG激光一样可有效和安全的实现手部皮肤的嫩肤,而且治疗期间的不适感和干燥感更少。

 

原始出处:

 

Katayoon Hadian, et al., Efficacy and safety of non-thermal nitrogen plasma versus long-pulsed Nd:YAG laser for hand rejuvenation. Lasers Med Sci. 2022 Feb;37(1):181-191. doi: 10.1007/s10103-020-03204-x.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878510, encodeId=d62718e8510d4, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 13:01:35 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004314, encodeId=ad4320043145e, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Mar 10 23:01:35 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721181, encodeId=79dd1e2118150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Feb 13 10:01:35 CST 2023, time=2023-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279820, encodeId=eed412e9820b3, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611538, encodeId=08be1611538c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=)]
    2022-12-07 anminleiryan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1878510, encodeId=d62718e8510d4, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 13:01:35 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004314, encodeId=ad4320043145e, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Mar 10 23:01:35 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721181, encodeId=79dd1e2118150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Feb 13 10:01:35 CST 2023, time=2023-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279820, encodeId=eed412e9820b3, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611538, encodeId=08be1611538c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1878510, encodeId=d62718e8510d4, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 13:01:35 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004314, encodeId=ad4320043145e, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Mar 10 23:01:35 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721181, encodeId=79dd1e2118150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Feb 13 10:01:35 CST 2023, time=2023-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279820, encodeId=eed412e9820b3, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611538, encodeId=08be1611538c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878510, encodeId=d62718e8510d4, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 13:01:35 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004314, encodeId=ad4320043145e, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Mar 10 23:01:35 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721181, encodeId=79dd1e2118150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Feb 13 10:01:35 CST 2023, time=2023-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279820, encodeId=eed412e9820b3, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611538, encodeId=08be1611538c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=)]
    2022-04-08 oliver169
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878510, encodeId=d62718e8510d4, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 13:01:35 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004314, encodeId=ad4320043145e, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Mar 10 23:01:35 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721181, encodeId=79dd1e2118150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Feb 13 10:01:35 CST 2023, time=2023-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279820, encodeId=eed412e9820b3, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611538, encodeId=08be1611538c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 08 10:01:35 CST 2022, time=2022-04-08, status=1, ipAttribution=)]

相关资讯

Am J Clin Dermatol:不同激光手段治疗非黑素瘤皮肤癌的疗效

手术是治疗非黑色素瘤皮肤癌的主要手段,激光是另一种选择选择。发表于Am J Clin Dermatol的一项回顾性研究对激光治疗非黑色素瘤皮肤癌进行了系统回顾和荟萃分析,以探究激光治疗非黑色素瘤皮肤癌

Nature子刊:激光加速质子束照射,用于肿瘤治疗

近期研究显示,使用比当前临床标准还高好几个数量级的超高辐射剂量率,也许比使用当前推荐的辐射剂量率更不容易破坏肿瘤细胞周围的健康组织,这种作用也被称为FLASH效应。

J Dermatolog Treat:激光治疗原发性局部皮肤淀粉样变性的效果如何?

原发性局部皮肤淀粉样变性(PLCA)是一种罕见的慢性疾病,其特征是错误折叠的不溶性淀粉样纤维蛋白聚合物的沉积,其治疗十分具有挑战性。激光治疗是目前治疗各种皮肤病的最受欢迎的方式之一。

脸上烦人的黄褐斑该如何祛除?

黄褐斑诊疗方案一网打尽。

Lasers Med Sci:低能量和低密度的二氧化碳点阵激光可有效进行面部光子嫩肤

低能量和低密度的二氧化碳点阵激光是面部光子嫩肤的一个安全和有效的选择。

J Dermatolog Treat:靶向UVB光疗联合钙泊三醇VS. 单纯靶向UVB治疗银屑病的疗效

银屑病是一种病因复杂的皮肤病,是一种由遗传和环境诱发的慢性、炎症性、免疫介导的全身性疾病。靶向紫外线和外用钙泊三醇经常被用于治疗银屑病,但钙泊三醇和靶向紫外线的联合效果一直存在争议。

Baidu
map
Baidu
map
Baidu
map